Selecta Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Cartesian Therapeutics

04/05/2023 14:32

* Selecta Biosciences Inc  SELB.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 9 cents per share.
    * Revenue fell 82.5% to $5.94 million from a year ago;
analysts
expected $11.83 million. 
    * Selecta Biosciences Inc's reported EPS for the quarter was
a
loss of 14 cents​.
    * The mean earnings estimate of analysts had risen by
about 20.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Selecta Biosciences Inc shares had fallen by 17.3% this
quarter and gained 1.8% so far this year.
    * The company reported a quarterly loss of $21.66 million.
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.09          -0.14          Missed
 Dec. 31 2022      -0.07          0.04           Beat
 Sep. 30 2022      -0.01          -0.05          Missed
 Jun. 30 2022      -0.08          0.06           Beat